Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Ensaio Clínico de Fase 2b do YN001 em Adultos com Aterosclerose Coronária (PURIFY-TIMI 81)

3 de novembro de 2026 atualizado por: Beijing Inno Medicine Co., Ltd.

Um Ensaio Clínico Randomizado, Multicêntrico, Duplo-cego, Paralelo, Controlado por Placebo de Fase 2b para Avaliar a Eficácia e Segurança do YN001 em Adultos com Aterosclerose Coronária

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Visão geral do estudo

Descrição detalhada

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Tipo de estudo

Intervencional

Inscrição (Estimado)

456

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • New South Wales
      • Penrith, New South Wales, Austrália, 2750
        • Recrutamento
        • Cannopy Clinical Research
        • Contato:
    • Queensland
      • Brisbane, Queensland, Austrália, 4064
        • Recrutamento
        • Core Research Group Pty Ltd.
        • Contato:
    • Victoria
      • Altona N., Victoria, Austrália, 3025
        • Recrutamento
        • Canopy Clinical Research
        • Contato:
    • Manitoba
      • Winnipeg, Manitoba, Canadá, R2H 2A6
        • Ainda não está recrutando
        • St. Boniface Hospital
        • Contato:
    • Ontario
      • London, Ontario, Canadá, N5A 5A5
        • Ainda não está recrutando
        • London Health Sciences Centre
        • Contato:
      • North York, Ontario, Canadá, M6B 3H7
        • Ainda não está recrutando
        • North York Diagnostic and Cardiac Centre
        • Contato:
      • Toronto, Ontario, Canadá, M5B 1W8
        • Ainda não está recrutando
        • St. Michael's Hospital
        • Contato:
      • Vaughan, Ontario, Canadá, L6A 4N9
        • Ainda não está recrutando
        • Cardiac Clinic
        • Contato:
    • Toronto
      • Toronto, Toronto, Canadá, M5G 2N2
        • Ainda não está recrutando
        • Toronto General Hospital - University Health Network
        • Contato:
    • An
      • Hefei, An, China, 230022
        • Recrutamento
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Contato:
          • Jianlong Wang, MD
          • Número de telefone: 0086-13681292304
          • E-mail: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, China, 230001
        • Recrutamento
        • Anhui Provincial Hospital
        • Contato:
          • Kangyu Chen, MD
          • Número de telefone: 0086 18056005099
          • E-mail: ustccky@126.com
        • Investigador principal:
          • Kangyu Chen, MD
        • Subinvestigador:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100035
        • Recrutamento
        • Beijing Jishuitan Hospital
        • Investigador principal:
          • Wei Liu, MD
        • Contato:
          • Qingwei Ji, MD
          • Número de telefone: 0086 18376642655
          • E-mail: jqwl24@163.cou
        • Investigador principal:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, China, 100029
        • Recrutamento
        • Anzhen Hospital
        • Contato:
        • Investigador principal:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, China, 101100
        • Ainda não está recrutando
        • Beijing Luhe Hospital
        • Contato:
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Recrutamento
        • Fujian Medical University Union Hospital
        • Contato:
        • Investigador principal:
          • Mingfang Ye, MD
        • Subinvestigador:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, China, 730030
        • Recrutamento
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Contato:
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
    • Heilongjiang
      • Daqing, Heilongjiang, China, 163316
        • Recrutamento
        • Daqing People's Hospital
        • Contato:
      • Harbin, Heilongjiang, China, 150001
        • Recrutamento
        • The First Affiliated Hospital of Harbin Medical University
        • Contato:
        • Investigador principal:
          • Lu Fu, MD
        • Investigador principal:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Recrutamento
        • Zhongnan Hospital of Wuhan University
        • Contato:
        • Investigador principal:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, China, 410008
        • Recrutamento
        • The Second Xiangya Hospital fo Central South University
        • Contato:
    • Jilin
      • Changchun, Jilin, China, 130033
        • Recrutamento
        • The First Hospital of Jilin University
        • Investigador principal:
          • Qian Tong, MD
        • Contato:
    • Liaoning
      • Shenyang, Liaoning, China, 110015
        • Recrutamento
        • The People's Hospital of Liaoning Province
        • Investigador principal:
          • Ying Liu, MD
        • Contato:
    • Shaanxi
      • Xi'an, Shaanxi, China, 710068
        • Recrutamento
        • Shaanxi Provincial People's Hospital
        • Contato:
    • Shandong
      • Jinan, Shandong, China
        • Recrutamento
        • Central Hospital Affiliated to Shandong First Medicial University
        • Contato:
          • Guohai Su, MD
          • Número de telefone: 0086 19953193319
          • E-mail: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Recrutamento
        • Fudan University-Zhongshan Hospital
        • Investigador principal:
          • Junbo Ge, MD
        • Contato:
        • Subinvestigador:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, China, 200001
        • Recrutamento
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Contato:
        • Investigador principal:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recrutamento
        • West China Hospital of Sichuan University
        • Contato:
        • Investigador principal:
          • Yong He, MD
      • Chengdu, Sichuan, China, 610072
        • Recrutamento
        • Sichuan Provincial People's Hospital
        • Contato:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300211
        • Recrutamento
        • The Second Hospital of Tianjin Medical University
        • Contato:
        • Investigador principal:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, China, 300121
        • Recrutamento
        • Tianjin People's Hospital
        • Investigador principal:
          • Zhuhua Yao, MD
        • Contato:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • Recrutamento
        • Zhejiang Provincial People's Hospital
        • Contato:
      • Suzhou, Zhejiang, China, 215006
        • Recrutamento
        • The First Affiliated Hospital of Soochow University
        • Contato:
      • Wenzhou, Zhejiang, China, 325000
        • Recrutamento
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Contato:
    • Alabama
      • Huntsville, Alabama, Estados Unidos, 35801-4312
        • Recrutamento
        • Heart Center Research, LLC
        • Contato:
    • California
      • Covina, California, Estados Unidos, 91740
      • Lincoln, California, Estados Unidos, 95648
        • Ainda não está recrutando
        • Clinical Trials Research
        • Contato:
      • Los Alamitos, California, Estados Unidos, 90720
        • Ainda não está recrutando
        • University of California Irvine Medical Center - Cardiovascular Center
        • Contato:
      • Stanford, California, Estados Unidos, 94305-2200
        • Ainda não está recrutando
        • Stanford Health Care General Cardiology
        • Contato:
      • Torrance, California, Estados Unidos, 90502-2006
        • Recrutamento
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Contato:
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33434
        • Ainda não está recrutando
        • Flourish Research - Boca Raton
        • Contato:
      • Hialeah, Florida, Estados Unidos, 33016-1895
        • Recrutamento
        • New Generation of Medical Research, LLC.
        • Contato:
      • St. Petersburg, Florida, Estados Unidos, 33709
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303-3049
        • Ainda não está recrutando
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Contato:
    • Idaho
      • Meridian, Idaho, Estados Unidos, 83642
        • Ainda não está recrutando
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Contato:
    • Illinois
      • Springfield, Illinois, Estados Unidos, 62781
        • Ainda não está recrutando
        • Southern Illinois University School of Medicine
        • Contato:
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66211-1215
        • Recrutamento
        • Midwest Heart & Vascular Specialists, LLC
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1032
        • Recrutamento
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Contato:
    • North Carolina
      • Raleigh, North Carolina, Estados Unidos, 27607
        • Ainda não está recrutando
        • NC Heart and Vascular Research, LLC
        • Contato:
      • Winston-Salem, North Carolina, Estados Unidos, 27104-3520
        • Ainda não está recrutando
        • Javara Inc. - Wake Forest University Health Sciences
        • Contato:
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73135
        • Ainda não está recrutando
        • South Oklahoma Heart Research, LLC
        • Contato:
    • Pennsylvania
      • Camp Hill, Pennsylvania, Estados Unidos, 17011
        • Recrutamento
        • Capital Area Research, LLC - Camp Hill
        • Contato:
    • Texas
      • Amarillo, Texas, Estados Unidos, 79106
        • Recrutamento
        • PharmaTex Research, LLC
        • Contato:
      • Carrollton, Texas, Estados Unidos, 75010
        • Ainda não está recrutando
        • Pulse Care Heart and Vascular
        • Contato:
      • Tomball, Texas, Estados Unidos, 77375
        • Ainda não está recrutando
        • DM Clinical Research - Dallas
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 80 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Experimental: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Comparador de Placebo: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Relative change from baseline in coronary NCPV at Week 13
Prazo: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Prazo: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Prazo: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Prazo: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Prazo: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Prazo: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Prazo: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Prazo: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Prazo: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Prazo: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Prazo: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Prazo: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Prazo: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Prazo: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Diretor de estudo: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de julho de 2026

Conclusão Primária (Estimado)

31 de julho de 2027

Conclusão do estudo (Estimado)

31 de março de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

2 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de abril de 2026

Primeira postagem (Real)

9 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

5 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

3 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • YN001-203
  • IND 157167 (Identificador de registro: Beijing Inno Medicine Co., Ltd.)

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever